05B · Claim Check

Barzolvolimab · Celldex Atopic dermatitis · NCT06727552

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 1 min read

Readout
Barzolvolimab · Celldex Atopic dermatitis · NCT06727552 (opens another website in a new tab)
What the registry or primary source says
Phase 2. Primary: percent change in itch score (PP-NRS) at week 16. N=131; active, not recruiting; primary completion 05.06.2026.
What the headline says
Primary missed at both doses; program stopped
Verdict
Match

Bookmarks need a Mind Club sign-in. How sign-in works

Read it in Claim Check